These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 18262712

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 3. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 4. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 6. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 10. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 11. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A.
    Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [Abstract] [Full Text] [Related]

  • 12. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH.
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [Abstract] [Full Text] [Related]

  • 13. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ, Zappa M, Määttänen L, Ciatto S.
    Prostate; 2007 Mar 01; 67(4):439-46. PubMed ID: 17192912
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH.
    Can J Urol; 2005 Jun 01; 12 Suppl 2():16-20. PubMed ID: 16018827
    [Abstract] [Full Text] [Related]

  • 18. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
    Roobol MJ, Schröder FH, Kranse R, ERSPC, Rotterdam.
    Prostate; 2006 May 01; 66(6):604-12. PubMed ID: 16388508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.